摘要
目的 :观察索他洛尔对房室旁道射频消融 (RFCA )患者 QT离散度 (QTd)及电生理作用的影响 ,对药物在术中应用的安全性作评估。 方法 :36例房室折返性心动过速 (AVRT)接受 RFCA的患者 ,随机分为对照组 (18例 ,单纯行 RFCA)和药物组 (18例 ,RFCA+顿服索他洛尔 16 0 m g)。药物组服药后每 30 min测量 1次电生理参数 ,观察 2 .5 h。两组在术前、术后分别测量 QTd。 结果 :两组术前 QTd无差异 ,对照组术前、术后 QTd无明显变化。药物组服药后 ,电生理参数与服药前比较相差显著 ,RFCA术前、术后 QTd分别为 (30 .9± 14.3)和 (2 4.7± 9.6 ) m s;QTcd分别为 (33.7± 17.1)和 (2 5 .2± 10 .1) m s;QTL cd分别为 (30 .8± 14.1)和 (2 5 .6± 19.4) m s,3项参数均 P<0 .0 5。两组术后比较 QTd,QTcd,QTL cd均有显著差异。结论 :索他洛尔可轻度降低 QTd,致心律失常的危险性较低 ,无器质性病变的 RFCA患者术中应用可帮助终止心动过速频繁发作 。
Objective: To observe the influence of sotalol on the QT dispersion in patients with atrioventricular accessory pathways underwent radiofrequency catheter ablation (RFCA). Methods: Thirty six patients were divided into 2 groups by random. One was the drug group(18 cases) treated by RFCA, and sotalol 160 mg was orally administered and intracardiac electrophysiological study was performed every 30 min for 5 times. The other group(control group, 18 cases) only treated by RFCA.QTd,QTcd and QTLcd were measured before and after RFCA. Results: There was no significant difference with QT dispersion before and after RFCA in control group. When compared with before RFCA, QTd in patients administered sotalol was (30.9±14.3) ms vs (24.7±9.6) ms; QTcd(33.7±17.1) ms vs (25.2±10.1) ms; QTLcd(30.8±14.1)ms vs (25.6±19.4) ms ( P <0.05). Conclusion: Sotalol can slightly lower QT dispersion, which is beneficial for preventing malignant ventricular arrthythmia. It is safe in RFCA in pateints with accessory pathway. [
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2001年第2期167-169,共3页
Academic Journal of Second Military Medical University
